BioCentury | Apr 1, 2020
Product Development

Chinese data propel InflaRx anti-complement mAb into clinic for severe COVID-19 pneumonia

Backed by preclinical and clinical data that support blocking complement to mitigate coronavirus-mediated respiratory distress, InflaRx has begun a clinical study of its own complement inhibitor to treat COVID-19 patients with severe pneumonia. InflaRx N.V....
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BC Extra | Jun 5, 2019
Clinical News

InflaRx stumbles after C5a mAb fails in inflammatory skin disease study

After reporting a high clinical response rate in a Phase IIa study, InflaRx lost $34.28 (92%) to $3.01 in afternoon trading Wednesday after all doses of IFX-1 failed to meet the primary endpoint in the...
BC Week In Review | May 11, 2018
Financial News

InflaRx raises $51M follow-on

Inflammatory diseases company InflaRx N.V. (NASDAQ:IFRX) raised $51 million on May 3 through the sale of 1.5 million shares at $34 in a follow-on underwritten by J.P. Morgan, Leerink, BMO Capital Markets and SunTrust Robinson...
BC Week In Review | Nov 10, 2017
Clinical News

InflaRx reports Phase IIa data of mAb against C5a for rare inflammatory skin disease

In September, InflaRx N.V. (NASDAQ:IFRX) reported data from a Phase IIa trial in 12 patients with moderate to severe hidradenitis suppurativa showing that IV IFX-1 (CaCP29) led to response rates of 75% at week 8...
BC Week In Review | Nov 10, 2017
Financial News

InflaRx prices $100M IPO

InflaRx N.V. (NASDAQ:IFRX) raised $100 million on Nov. 8 through the sale of 6.7 million shares at $15 in an IPO underwritten by JPMorgan, Leerink and BMO Capital Markets. The share price is at the...
BC Extra | Nov 8, 2017
Financial News

InflaRx prices $100M IPO

InflaRx N.V. (NASDAQ:IFRX) raised $100 million on Wednesday through the sale of 6.7 million shares at $15 in an IPO underwritten by JPMorgan, Leerink and BMO Capital Markets. The share price is at the midpoint...
BC Week In Review | Oct 13, 2017
Financial News

InflaRx raises $55M in series D

InflaRx GmbH (Jena, Germany) raised $55 million in a series D round from Bain Capital Life Sciences, Cormorant Asset Management, RA Capital and undisclosed funds managed by a U.S. firm. InflaRx said the round included...
BC Extra | Oct 13, 2017
Financial News

InflaRx raises $55M in series D round

InflaRx GmbH (Jena, Germany) raised $55 million in a series D round from Bain Capital Life Sciences, Cormorant Asset Management, RA Capital and undisclosed funds managed by a U.S. firm. InflaRx said the round included...
BC Week In Review | Jan 6, 2017
Clinical News

IFX-1: Ph II started

InflaRx began an open-label, Greek Phase II trial to evaluate once-weekly IV IFX-1 for 8 weeks in 12 patients who have failed previous antibiotic or biological treatment. InflaRx GmbH , Jena, Germany  Product: CaCP29 , IFX-1  ...
Items per page:
1 - 10 of 16